On 4 September 2026, Alphamab Oncology executed an on-market repurchase of 56,000 ordinary shares on the Hong Kong Stock Exchange, paying between HKD 8.75 and HKD 8.80 per share. The volume-weighted average price was HKD 8.79, bringing total consideration to approximately HKD 0.49 million.

Following the transaction, issued shares outstanding (excluding treasury stock) declined to 968.00 million, while treasury shares increased to 6.38 million. The repurchased shares represent 0.0058 % of the company’s pre-transaction issued share capital.

The buyback forms part of the mandate approved on 12 June 2026, which authorises Alphamab Oncology to repurchase up to 96.85 million shares. Cumulative buybacks under this mandate now total 506,000 shares, equivalent to 0.05 % of the share base as at the mandate date.

In line with Hong Kong Listing Rules, Alphamab Oncology is restricted from issuing new shares or disposing of treasury shares until 4 October 2026.